The quarter's performance was characterised by robust revenue growth of 12.78% YoY to ₹6,303.50 crores, accompanied by notable margin expansion. Operating profit margins (excluding other income) improved to 14.93%, the highest in recent quarters, whilst PAT margins expanded to 7.84% from 7.08% in the corresponding quarter last year. Sequential momentum remained strong, with net profit growing 10.26% quarter-on-quarter, underscoring the sustainability of the company's growth trajectory.
Apollo Hospitals' Q2 FY26 results reflect the company's ability to capitalise on India's growing healthcare demand whilst maintaining disciplined cost management. The quarter witnessed accelerated sequential revenue growth of 7.90%, up from 4.47% in Q1 FY26, indicating strengthening business momentum. The company's diverse revenue streams—spanning tertiary care hospitals, pharmacies, primary care clinics, and diagnostics—continue to provide resilience against sector-specific headwinds.
Quarterly Performance Trend: Sustained Momentum Across Metrics
| Metric | Sep'25 | Jun'25 | Mar'25 | Dec'24 | Sep'24 |
|---|---|---|---|---|---|
| Net Sales (₹ Cr) | 6,303.50 | 5,842.10 | 5,592.20 | 5,526.90 | 5,589.30 |
| QoQ Growth | +7.90% | +4.47% | +1.18% | -1.12% | — |
| YoY Growth | +12.78% | +14.88% | +13.11% | — | — |
| Operating Profit (₹ Cr) | 941.10 | 851.90 | 769.70 | 761.50 | 815.50 |
| Operating Margin % | 14.93% | 14.58% | 13.76% | 13.78% | 14.59% |
| Net Profit (₹ Cr) | 477.20 | 432.80 | 389.60 | 372.30 | 378.80 |
| PAT Margin % | 7.84% | 7.55% | 7.41% | 6.86% | 7.08% |
The quarterly trend analysis reveals consistent improvement across all key metrics. Operating profit margins have expanded by 117 basis points YoY to 14.93%, driven by better capacity utilisation and operational efficiencies. Net profit margins have similarly improved by 76 basis points to 7.84%, reflecting improved profitability at the bottom line. The company's ability to maintain double-digit revenue growth whilst expanding margins demonstrates strong pricing power and operational excellence.
Financial Performance: Margin Expansion Drives Profitability
Apollo Hospitals' Q2 FY26 financial performance was characterised by strong top-line growth and impressive margin expansion. Net sales of ₹6,303.50 crores represented the highest quarterly revenue in the company's history, growing 12.78% YoY and 7.90% QoQ. The acceleration in sequential growth compared to Q1 FY26 indicates strengthening demand across the company's hospital network and allied businesses.
Operating profit (PBDIT excluding other income) reached ₹941.10 crores in Q2 FY26, marking a 15.40% YoY increase and 10.47% QoQ growth. Operating margins expanded to 14.93%, the highest level in at least eight quarters, surpassing the 14.59% recorded in Sep'24. This margin improvement was achieved despite employee costs rising to ₹766.70 crores, reflecting the company's effective cost management and operating leverage.
Interest costs remained well-controlled at ₹109.60 crores, declining 6.72% YoY despite higher debt levels, indicating favourable refinancing and improved debt management. Depreciation increased to ₹217.80 crores from ₹184.50 crores YoY, reflecting ongoing capital expenditure and capacity expansion initiatives. The company's profit before tax reached ₹674.70 crores, up 21.04% YoY, whilst the effective tax rate moderated to 26.78% from 29.01% in the year-ago quarter, providing an additional boost to net profitability.
The quality of earnings remained robust, with consolidated net profit of ₹477.20 crores closely tracking standalone PAT of ₹487.70 crores. The 25.98% YoY growth in consolidated net profit outpaced revenue growth, demonstrating strong operational leverage and margin expansion. On a half-yearly basis (H1 FY26), the company reported consolidated net profit of ₹910.00 crores, up 33.26% YoY, underscoring the sustainability of the improved performance trajectory.
Operational Excellence: Capital Efficiency at Multi-Year Highs
Apollo Hospitals' operational performance in Q2 FY26 showcased exceptional capital efficiency, with return on equity (ROE) reaching 17.61%, significantly higher than the five-year average of 12.07%. This substantial improvement in ROE reflects the company's enhanced profitability and more efficient deployment of shareholder capital. Higher ROE is a clear indicator of superior management effectiveness and value creation for shareholders, positioning Apollo Hospitals favourably within the healthcare sector.
Return on capital employed (ROCE) similarly improved to 17.05% for the latest period, up from the five-year average of 15.07%. The company's ROCE has been on an upward trajectory, with half-yearly ROCE for H1 FY26 reaching 15.54%, the highest in recent periods. This improvement in ROCE demonstrates Apollo's ability to generate strong returns from its invested capital base, a critical metric for capital-intensive healthcare businesses requiring continuous infrastructure investment.
Capital Efficiency Highlights
ROE at 17.61%: Significantly above the five-year average of 12.07%, reflecting superior capital efficiency and profitability. Higher ROE indicates better management effectiveness and stronger value creation for shareholders.
ROCE at 17.05%: Improved from 15.07% five-year average, demonstrating enhanced returns on invested capital despite ongoing capacity expansion.
Operating Profit to Interest Coverage: Reached 8.59 times in Q2 FY26, the highest level in recent quarters, indicating robust debt servicing capability and financial stability.
The company's balance sheet strength has improved markedly, with shareholder funds increasing to ₹8,212.30 crores as of March 2025, up 18.41% from ₹6,935.40 crores in March 2024. Long-term debt stood at ₹4,417.00 crores, resulting in a net debt-to-equity ratio of 0.62, which remains within manageable limits for a growth-oriented healthcare provider. The company's debt-to-EBITDA ratio of 2.44 times indicates moderate leverage, providing financial flexibility for future expansion initiatives.
Cash flow generation remained robust, with operating cash flow of ₹2,136.00 crores for FY25, up 11.25% from ₹1,920.00 crores in FY24. The company deployed ₹3,380.00 crores in investing activities during FY25, primarily towards capacity expansion and infrastructure upgrades across its hospital network. Despite significant capital expenditure, the company maintained positive net cash inflow of ₹72.00 crores, with closing cash and equivalents at ₹578.00 crores, ensuring adequate liquidity for operational requirements.
✓ Key Operational Strengths:
ROE Improvement: ROE of 17.61% represents a substantial improvement from the historical average of 12.07%, reflecting enhanced profitability and superior capital efficiency. This higher ROE demonstrates management's effectiveness in generating returns for shareholders.
Strong Interest Coverage: Operating profit to interest coverage of 8.59 times provides comfortable cushion for debt servicing, significantly above the five-year average of 3.94 times.
Healthy Cash Generation: Operating cash flow of ₹2,136.00 crores in FY25 demonstrates strong underlying business fundamentals and ability to fund growth organically.
Healthcare Sector Dynamics: Riding India's Healthcare Wave
Apollo Hospitals operates in India's rapidly expanding private healthcare sector, which continues to benefit from favourable structural tailwinds. Rising disposable incomes, increasing health awareness, growing prevalence of lifestyle diseases, and improving insurance penetration are driving sustained demand for quality healthcare services. The company's position as India's largest private hospital chain, with a market capitalisation of ₹1,11,196 crores, provides significant competitive advantages in terms of brand recognition, clinical expertise, and economies of scale.
The hospital industry has demonstrated resilient growth, with the sector delivering 27.00% returns over the past year. However, Apollo Hospitals' stock return of 11.83% over the same period has underperformed the sector by 15.17 percentage points, suggesting potential valuation concerns or company-specific challenges that have weighed on investor sentiment. Despite this near-term underperformance, the company's long-term fundamentals remain strong, supported by consistent revenue growth of 15.76% CAGR over five years and EBIT growth of 31.00% CAGR over the same period.
The competitive landscape in India's hospital sector remains fragmented, with Apollo Hospitals, Max Healthcare, Fortis Healthcare, Narayana Hrudayalaya, and Aster DM Healthcare constituting the major organised players. Apollo's diversified presence across 16 cities, coupled with its integrated healthcare ecosystem encompassing hospitals, pharmacies, diagnostics, and primary care clinics, provides a sustainable competitive moat. The company's focus on tertiary and quaternary care services, which command premium pricing, differentiates it from peers focused primarily on secondary care.
| Growth Metric | 5-Year CAGR | Assessment |
|---|---|---|
| Net Sales Growth | 15.76% | Healthy long-term revenue expansion |
| EBIT Growth | 31.00% | Strong operating leverage and margin improvement |
| PAT Growth (FY25 vs FY24) | 60.52% | Exceptional profitability improvement |
Looking ahead, Apollo Hospitals is well-positioned to capitalise on India's healthcare sector growth, supported by ongoing capacity expansion, digital health initiatives, and potential consolidation opportunities in fragmented regional markets. The company's established brand equity and clinical excellence provide a strong foundation for sustained market share gains, particularly in high-margin tertiary and quaternary care segments.
Industry Leadership: Valuation Premium Reflects Market Position
Apollo Hospitals' competitive positioning within the hospital sector reflects its status as the industry leader by market capitalisation. However, the company's valuation metrics present a mixed picture when compared to peers, with some metrics commanding a premium whilst others suggest relative undervaluation.
| Company | P/E (TTM) | P/BV | ROE % | Debt/Equity | Div Yield % |
|---|---|---|---|---|---|
| Apollo Hospitals | 71.27 | 13.66 | 12.07 | 0.62 | 0.24 |
| Max Healthcare | 90.94 | 11.68 | 10.19 | 0.25 | 0.13 |
| Fortis Healthcare | 82.55 | 8.55 | 5.80 | 0.22 | 0.10 |
| Narayana Hrudayalaya | 47.03 | 10.26 | 20.13 | 0.22 | 0.25 |
| Aster DM Healthcare | 98.36 | 10.36 | 17.50 | 0.19 | 0.71 |
| Global Health | 60.28 | 10.18 | 15.90 | -0.12 | 0.04 |
Apollo Hospitals trades at a P/E ratio of 71.27 times, below the peer group average of approximately 76 times, suggesting relative undervaluation on an earnings basis. However, the company commands the highest price-to-book ratio of 13.66 times compared to the peer average of approximately 10.2 times, reflecting the market's recognition of Apollo's superior asset quality, brand value, and market leadership position.
The company's ROE of 12.07% (five-year average) trails several peers, including Narayana Hrudayalaya (20.13%), Aster DM Healthcare (17.50%), and Global Health (15.90%). However, Apollo's latest ROE of 17.61% demonstrates significant improvement and narrows this gap considerably. The company's debt-to-equity ratio of 0.62 is higher than most peers, reflecting its aggressive capacity expansion strategy, but remains within manageable limits and is supported by strong cash flow generation.
Apollo's dividend yield of 0.24% is modest compared to Aster DM Healthcare's 0.71% and Narayana Hrudayalaya's 0.25%, reflecting the company's preference for reinvesting cash flows into growth initiatives rather than maximising dividend payouts. The dividend payout ratio of 25.60% provides flexibility for future dividend increases as profitability continues to improve.
Valuation Analysis: Attractive Entry Point for Long-Term Investors
Apollo Hospitals' current valuation presents an interesting proposition for investors, with the stock trading at ₹7,799.90 as of November 6, 2025, approximately 3.69% below its 52-week high of ₹8,099.00 and 29.95% above its 52-week low of ₹6,002.15. The company's valuation grade has recently improved to "Attractive" from "Fair" on November 3, 2025, suggesting improving value at current price levels.
The stock trades at a P/E ratio of 71.27 times trailing twelve-month earnings, which appears elevated in absolute terms but is below the industry average P/E of 70 times. Given the company's strong earnings growth trajectory—with Q2 FY26 net profit up 25.98% YoY—and improving return ratios, the current P/E multiple appears justifiable. The PEG ratio of 1.37 suggests the stock is reasonably valued relative to its growth prospects, with a ratio below 2.0 generally considered attractive for growth stocks.
The company's price-to-book ratio of 13.66 times is significantly higher than peers, justified by Apollo's superior brand value, market leadership, and improving return ratios. With ROE expanding to 17.61%, the premium P/BV multiple is supported by the company's ability to generate strong returns on equity capital. The EV/EBITDA multiple of 36.65 times reflects the market's expectations for continued earnings growth and margin expansion.
Apollo's EV/Capital Employed ratio of 8.82 times appears attractive given the company's ROCE of 17.05%, implying an earnings yield of approximately 11.4% on enterprise value. This compares favourably to the cost of capital for most investors and suggests the market is not fully pricing in the company's improving capital efficiency. The EV/Sales ratio of 5.20 times reflects the premium nature of Apollo's service offerings and its strong brand positioning.
Valuation Verdict
At current levels, Apollo Hospitals offers an attractive risk-reward proposition for long-term investors. The recent upgrade to "Attractive" valuation, combined with improving operational metrics and strong earnings momentum, suggests the stock provides good value. Whilst the absolute P/E multiple appears elevated, it is justified by robust earnings growth, expanding margins, and improving return ratios. The stock's 11.83% one-year return lags the sector, potentially offering a catch-up opportunity as the market recognises the company's improved fundamentals.
Shareholding: Institutional Confidence Building Despite Promoter Stake Reduction
Apollo Hospitals' shareholding pattern reveals interesting dynamics, with promoter holding declining significantly to 8.58% in September 2025 from 13.11% in June 2025, representing a substantial 4.53 percentage point sequential reduction. This marks a continuation of the promoter stake reduction trend, with holdings declining from 13.99% in September 2024 to the current level. Whilst promoter stake reductions can sometimes raise concerns, in Apollo's case, the reduction appears to be part of a structured deleveraging or portfolio rebalancing exercise by the promoter group.
| Shareholder Category | Sep'25 | Jun'25 | Mar'25 | Dec'24 | QoQ Change |
|---|---|---|---|---|---|
| Promoter Holding | 8.58% | 13.11% | 13.47% | 13.47% | -4.53% |
| FII Holding | 44.20% | 43.49% | 42.74% | 45.27% | +0.71% |
| Mutual Fund Holding | 16.48% | 15.94% | 15.42% | 12.77% | +0.54% |
| Insurance Holdings | 3.46% | 4.36% | 5.93% | 6.02% | -0.90% |
| Other DII Holdings | 1.41% | 1.27% | 1.16% | 1.42% | +0.14% |
| Non-Institutional | 6.43% | 5.61% | 5.41% | 5.19% | +0.82% |
Offsetting the promoter stake reduction, foreign institutional investors (FIIs) have steadily increased their holdings, with FII stake rising to 44.20% in September 2025 from 43.49% in June 2025 and 42.74% in March 2025. This consistent increase in FII participation over three consecutive quarters signals growing international investor confidence in Apollo's growth prospects and improving fundamentals. FII holdings now represent the largest shareholder category, reflecting the stock's attractiveness to sophisticated global investors.
Domestic mutual funds have similarly demonstrated strong conviction, with holdings increasing to 16.48% in September 2025 from 15.94% in June 2025 and 15.42% in March 2025. The mutual fund stake has grown by 2.65 percentage points from December 2024 levels of 12.77%, indicating sustained buying by domestic institutional investors. The presence of 349 mutual fund schemes holding Apollo Hospitals stock underscores broad-based institutional support.
Insurance company holdings declined to 3.46% in September 2025 from 4.36% in June 2025, representing a 0.90 percentage point reduction. This follows a more significant decline from 5.93% in March 2025, suggesting some profit-booking by insurance investors following the stock's strong run. However, total institutional holdings (FII + MF + Insurance + Other DII) remain robust at 65.55%, providing a stable shareholder base and reducing stock volatility.
The increase in non-institutional holdings to 6.43% from 5.61% suggests growing retail investor interest in the stock, potentially driven by the company's improving financial performance and positive media coverage. The presence of 1,184 FII entities holding the stock indicates widespread international institutional participation, whilst 349 mutual fund schemes reflect strong domestic institutional support.
Stock Performance: Solid Long-Term Returns Despite Near-Term Consolidation
Apollo Hospitals' stock performance presents a tale of two timeframes—exceptional long-term wealth creation tempered by near-term consolidation and sector underperformance. Over the past decade, the stock has delivered remarkable returns of 480.09%, significantly outperforming the Sensex's 217.19% return by an impressive 262.90 percentage points. This long-term outperformance reflects the company's successful execution of its growth strategy and the structural tailwinds in India's healthcare sector.
| Period | Apollo Return | Sensex Return | Alpha |
|---|---|---|---|
| 1 Week | 0.15% | -1.30% | +1.45% |
| 1 Month | 1.76% | 1.86% | -0.10% |
| 3 Months | 8.52% | 3.44% | +5.08% |
| 6 Months | 11.27% | 3.31% | +7.96% |
| Year to Date | 6.90% | 6.62% | +0.28% |
| 1 Year | 11.83% | 3.65% | +8.18% |
| 3 Years | 78.91% | 36.69% | +42.22% |
| 5 Years | 273.92% | 98.87% | +175.05% |
| 10 Years | 480.09% | 217.19% | +262.90% |
Medium-term returns remain robust, with the stock delivering 78.91% over three years and 273.92% over five years, both substantially ahead of benchmark indices. The three-year alpha of 42.22 percentage points and five-year alpha of 175.05 percentage points underscore Apollo's ability to generate superior risk-adjusted returns for shareholders over meaningful investment horizons.
However, near-term performance has been more subdued, with the stock gaining 11.83% over the past year, outperforming the Sensex by 8.18 percentage points but underperforming the hospital sector's 27.00% return by 15.17 percentage points. This sector underperformance suggests that whilst Apollo has delivered positive absolute returns, some peers have performed better, potentially due to lower valuations or stronger near-term growth catalysts.
The stock's technical positioning shows a "Mildly Bullish" trend as of October 24, 2025, having transitioned from "Bullish" on October 27, 2025. The stock trades at ₹7,799.90, slightly below its 20-day moving average of ₹7,814.79 and 50-day moving average of ₹7,763.11, indicating near-term consolidation. However, the stock remains well above its 200-day moving average of ₹7,130.72, suggesting the long-term uptrend remains intact.
Risk-adjusted returns over one year show a Sharpe ratio of 0.53 with volatility of 22.36%, compared to the Sensex's Sharpe ratio of 0.29 and volatility of 12.45%. The higher volatility reflects the stock's beta of 1.00, indicating it moves in line with the broader market. The stock is classified as "Low Risk Medium Return," suggesting a balanced risk-reward profile suitable for investors with moderate risk tolerance.
Investment Thesis: Quality Healthcare Play with Improving Fundamentals
Apollo Hospitals' investment thesis rests on four key pillars: attractive valuation following recent correction, good quality fundamentals, positive financial trend, and constructive technical setup. The company's proprietary Mojo score of 71/100 places it in the "Buy" category, reflecting a balanced assessment across multiple parameters.
The company's quality grade of "Good" reflects its solid long-term financial performance, with five-year sales CAGR of 15.76% and EBIT CAGR of 31.00% demonstrating consistent growth and improving profitability. The quality assessment is supported by healthy institutional participation of 65.55%, market leadership position, and improving return ratios. However, the company's average debt-to-EBITDA ratio of 2.44 times and interest coverage of 3.94 times (average) indicate moderate leverage that requires monitoring.
The positive financial trend designation for Q2 FY26 is underpinned by multiple record metrics: highest-ever quarterly net sales of ₹6,303.50 crores, highest operating profit of ₹941.10 crores, highest operating margin of 14.93%, and highest quarterly PAT of ₹477.20 crores. The company's operating profit-to-interest coverage of 8.59 times in Q2 FY26 represents the highest level in recent quarters, indicating robust debt servicing capability.
From a valuation perspective, the recent upgrade to "Attractive" on November 3, 2025, suggests improving value at current price levels. The stock's P/E of 71.27 times, whilst elevated in absolute terms, is justified by strong earnings growth momentum and improving return ratios. The PEG ratio of 1.37 indicates reasonable valuation relative to growth prospects, whilst the EV/Capital Employed ratio of 8.82 times appears attractive given the company's ROCE of 17.05%.
Key Strengths & Risk Factors
✓ KEY STRENGTHS
- Market Leadership: India's largest private hospital chain with ₹1,11,196 crore market cap and pan-India presence across 16 cities
- Strong Capital Efficiency: ROE improved to 17.61% from 12.07% average, demonstrating superior management effectiveness and value creation
- Consistent Growth: Five-year sales CAGR of 15.76% and EBIT CAGR of 31.00% reflect robust operational execution
- Margin Expansion: Operating margins at 14.93% in Q2 FY26, highest in eight quarters, with 117 bps YoY improvement
- Strong Earnings Momentum: Q2 FY26 net profit up 25.98% YoY, with sequential growth of 10.26% indicating sustained trajectory
- Improving Debt Metrics: Operating profit-to-interest coverage of 8.59 times in Q2 FY26, highest in recent quarters
- Institutional Confidence: 65.55% institutional holdings with FII and MF stakes increasing consistently over recent quarters
⚠ KEY CONCERNS
- Promoter Stake Reduction: Promoter holding declined sharply to 8.58% from 13.11% in Q2 FY26, raising questions about promoter conviction
- Elevated Leverage: Debt-to-equity ratio of 0.62 and debt-to-EBITDA of 2.44 times higher than most peers, limiting financial flexibility
- Sector Underperformance: One-year stock return of 11.83% lags hospital sector's 27.00% return by 15.17 percentage points
- Premium Valuation: P/BV of 13.66 times significantly higher than peer average of ~10.2 times, leaving limited margin of safety
- Capital Intensity: Healthcare business requires continuous capital expenditure for capacity expansion and equipment upgrades
- Regulatory Risks: Healthcare sector subject to price controls, regulatory changes, and potential government intervention
- Competition Intensifying: Growing competition from established players and new entrants in key markets could pressure margins
Outlook: What Lies Ahead
✓ POSITIVE CATALYSTS
- Sustained Margin Expansion: Operating margins continuing above 15% driven by operating leverage and better capacity utilisation
- Capacity Additions: New hospitals and bed additions coming online, driving revenue growth acceleration
- Digital Health Initiatives: Telemedicine and digital health platforms expanding reach and improving margins
- Improving ROE Trajectory: ROE sustaining above 17% levels, validating premium valuation multiples
- Market Share Gains: Consolidation opportunities in fragmented regional markets enhancing competitive position
⚠ RED FLAGS TO MONITOR
- Further Promoter Stake Dilution: Continued reduction in promoter holding below current 8.58% levels
- Margin Pressure: Operating margins declining below 14% due to competitive pressures or cost inflation
- Debt Levels Rising: Debt-to-EBITDA ratio increasing above 3.0 times, constraining financial flexibility
- Earnings Growth Deceleration: Quarterly profit growth falling below 15% YoY for consecutive quarters
- Institutional Exodus: FII or mutual fund holdings declining for two consecutive quarters
Apollo Hospitals Enterprise Ltd. stands at an inflection point, with improving operational metrics, expanding margins, and strong earnings momentum supporting the investment case. The company's position as India's largest and most recognised private hospital chain, combined with its diversified healthcare ecosystem, provides a strong competitive moat in a structurally growing sector.
The recent improvement in return on equity to 17.61%—significantly above the historical average of 12.07%—demonstrates management's enhanced capital efficiency and ability to generate superior returns for shareholders. This improvement in ROE, coupled with operating margin expansion to 14.93%, validates the company's operational excellence and justifies the premium valuation multiples.
However, investors must remain cognisant of the risks. The sharp reduction in promoter stake to 8.58%, whilst potentially part of a planned deleveraging exercise, warrants monitoring. The company's elevated debt levels and capital-intensive business model require sustained cash flow generation to service debt whilst funding growth. Additionally, the stock's underperformance relative to the hospital sector over the past year suggests some peers may offer better near-term value.
For long-term investors with a three-to-five-year investment horizon, Apollo Hospitals offers an attractive proposition to participate in India's healthcare growth story through a market leader with improving fundamentals. The stock's recent consolidation and upgrade to "Attractive" valuation provide a reasonable entry point, particularly for investors seeking exposure to India's structural healthcare themes.
The Verdict: Quality Healthcare Play with Improving Fundamentals
Score: 71/100
For Fresh Investors: Recommended for fresh buy. Current levels offer an attractive entry point for long-term investors seeking exposure to India's healthcare sector through a market leader with improving profitability and expanding margins. The stock's "Attractive" valuation grade, combined with positive financial trends and good quality fundamentals, supports accumulation on dips.
For Existing Holders: Continue to hold with a long-term perspective. The company's record Q2 FY26 performance, improving capital efficiency (ROE at 17.61%), and sustained margin expansion validate the investment thesis. Monitor promoter stake trends and debt levels closely. Consider averaging up on meaningful corrections below ₹7,500 levels.
Fair Value Estimate: ₹8,400 (7.7% upside from current levels)
Investment Rationale: Apollo Hospitals' BUY rating is supported by strong operational execution, record quarterly profitability, improving return ratios, and attractive valuation following recent consolidation. The company's market leadership, diversified healthcare ecosystem, and exposure to India's structural healthcare growth provide a compelling long-term investment case, despite near-term concerns around promoter stake reduction and elevated leverage.
Note— ROCE = (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. The author and publisher are not responsible for any investment decisions made based on this analysis.
